Advicenne SA (DE:3MM)
FRANKFURT:3MM
3MM Stock Chart & Stats
€1.67
€0.03(1.75%)
At close: 4:00 PM EST
€1.67
€0.03(1.75%)
Day’s Range― - ―
52-Week Range€0.81 - €2.20
Previous CloseN/A
Volume0.00
Average Volume (3M)53.00
Market Cap
€16.16M
Enterprise Value€30.38M
Total Cash (Recent Filing)€1.34M
Total Debt (Recent Filing)€19.00M
Price to Earnings (P/E)―
Beta0.50
Next Earnings
Sep 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.72
Shares Outstanding14,609,619
10 Day Avg. Volume61
30 Day Avg. Volume53
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)-0.87
Price to Sales (P/S)3.81
P/FCF Ratio-5.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.21
Revenue Forecast (FY)€7.20M
Bulls Say, Bears Say
Bulls Say
Orphan / Specialty Product FocusA focused specialty product for a rare, chronic renal disorder creates durable demand per patient and high clinical switching costs. For a small patient base, consistent prescription use and clinical necessity support steady long-term revenue once penetration and reimbursement are in place.
Reimbursement-driven Revenue ModelA commercialization model tied to prescription sales and formal reimbursement builds predictable, recurring revenue streams in covered markets. Reimbursement and specialty distribution reduce price sensitivity and support longer treatment durations, aiding durable cash generation when uptake scales.
Improving Gross ProfitabilityA move to positive gross margins signals improved unit economics from pricing, manufacturing scale or mix shift. Sustained gross profitability is a structural enabler for future operating leverage, making net profitability achievable if SG&A and R&D are controlled over the medium term.
Bears Say
Negative Equity / Fragile Capital StructureProlonged negative shareholders' equity materially weakens financial flexibility and increases default or covenant risk. It constrains access to debt without costly terms or dilution via equity raises, and remains a structural vulnerability until restored by profits or meaningful capital injections.
Consistent Cash BurnPersistent negative operating and free cash flow forces reliance on external financing, raising dilution and refinancing risk. This curtails the firm's ability to invest in commercial expansion or R&D sustainably and is a lasting constraint until positive cash generation is achieved.
Small, Volatile And Falling RevenueVolatile, small top-line and a 2025 decline indicate weak market penetration or uptake issues. Without steady revenue growth, the company cannot realize scale benefits, maintain margin improvements, or self-fund operations—making commercial viability and profitability uncertain over the medium term.
Advicenne SA News
3MM FAQ
What was Advicenne SA’s price range in the past 12 months?
Advicenne SA lowest stock price was €0.81 and its highest was €2.20 in the past 12 months.
What is Advicenne SA’s market cap?
Advicenne SA’s market cap is €16.16M.
When is Advicenne SA’s upcoming earnings report date?
Advicenne SA’s upcoming earnings report date is Sep 17, 2026 which is in 95 days.
How were Advicenne SA’s earnings last quarter?
Advicenne SA released its earnings results on Mar 26, 2026. The company reported -€0.314 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.314.
Is Advicenne SA overvalued?
According to Wall Street analysts Advicenne SA’s price is currently Overvalued.
Does Advicenne SA pay dividends?
Advicenne SA does not currently pay dividends.
What is Advicenne SA’s EPS estimate?
Advicenne SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Advicenne SA have?
Advicenne SA has 14,609,619 shares outstanding.
What happened to Advicenne SA’s price movement after its last earnings report?
Advicenne SA reported an EPS of -€0.314 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 15.881%.
Which hedge fund is a major shareholder of Advicenne SA?
Currently, no hedge funds are holding shares in DE:3MM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Advicenne SA
Advicenne S.A. operates as a specialized pharmaceutical firm, focusing on the innovation and commercialization of therapeutic solutions for various kidney-related disorders. The company's primary offering, Sibnayal, targets both distal renal tubular acidosis and cystinuria. Established in 2007, Advicenne S.A. maintains its principal offices in Paris, France.